Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High After Better-Than-Expected Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) shares hit a new 52-week high during trading on Tuesday following a stronger than expected earnings report. The stock traded as high as $303.00 and last traded at $292.3520, with a volume of 123047 shares changing hands. The stock had previously closed at $286.95.

The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%.

Krystal Biotech News Roundup

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q1 beat — Krystal reported $1.83 EPS vs. $1.45 expected and $116.4M in revenue, driven by VYJUVEK sales and delivering strong margins that support profitability momentum. Zacks: KRYS Tops Q1
• Positive Sentiment: Operational and pipeline progress — company press release: $116.4M VYJUVEK global revenue, enrollment complete in KB803 (DEB corneal study), on track for KB803 and KB801 registrational readouts in 2026, and FDA platform technology designation for KB407 and KB111; strong cash balance (~$1.0B) supports upcoming milestones. Press Release
• Positive Sentiment: Analyst support — HC Wainwright raised Q2–Q4 2026 EPS forecasts (Q2 to $1.59, Q3 to $1.74, Q4 to $1.74) and reiterated a Buy with a $310 price target, signaling confidence in near‑term earnings power and leaving room for additional upside. (Coverage note reported by MarketBeat/Benzinga)
• Positive Sentiment: Market reaction and momentum — multiple outlets noted the stock’s rise after the earnings release and call as investors price in product revenue growth and upcoming data readouts as key catalysts. Investing.com
• Neutral Sentiment: Earnings call and detail flow — full call transcript and summaries are available for deeper review of commercial cadence, international rollout and R&D timelines; useful for modeling but no new guidance was issued. Earnings Call Transcript
• Neutral Sentiment: Valuation note — the stock trades at a relatively rich multiple (PE ~42.8) reflecting high growth expectations; this raises sensitivity to any delays or mixed clinical readouts. (Background metric investors should consider.)

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Jefferies Financial Group upped their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday. Citigroup restated a “buy” rating on shares of Krystal Biotech in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $323.33.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the sale, the chief accounting officer owned 22,366 shares in the company, valued at $5,985,141.60. This represents a 3.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the sale, the insider owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 129,164 shares of company stock worth $34,538,578 in the last quarter. 13.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Krystal Biotech during the 1st quarter valued at $218,000. Finally, Cetera Investment Advisers raised its holdings in shares of Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.4%

The firm has a market cap of $8.56 billion, a P/E ratio of 42.95 and a beta of 0.50. The business’s fifty day moving average price is $261.72 and its two-hundred day moving average price is $246.50.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.